CervoMed Inc CRVO.OQ CRVO.O is expected to show a fall in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report a 26.6% decrease in revenue to $1.722 million from $2.35 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for CervoMed Inc is for a loss of 66 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 5.8% in the last three months.
Wall Street's median 12-month price target for CervoMed Inc is $15.00, above its last closing price of $8.49.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.68 | -0.63 | -0.80 | Missed | -27 |
Sep. 30 2024 | -0.40 | -0.41 | -0.55 | Missed | -33.3 |
Jun. 30 2024 | -0.26 | -0.31 | -0.27 | Beat | 11.8 |
Mar. 31 2024 | -0.39 | -0.39 | -0.41 | Missed | -5.1 |
Dec. 31 2023 | -0.29 | -0.29 | -0.38 | Missed | -31 |
Sep. 30 2023 | -0.95 | -0.95 | -0.70 | Beat | 26.3 |
This summary was machine generated May 10 at 00:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)